Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.


The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page


My NCBI Filters

Results by year

Table representation of search results timeline featuring number of search results per year.

Year Number of Results
1946 1
1947 2
1949 1
1951 1
1954 1
1959 1
1964 1
1970 1
1972 1
1982 2
1983 2
1984 3
1986 2
1987 2
1989 5
1990 8
1991 4
1992 4
1993 2
1994 2
1995 4
1996 6
1997 4
1998 13
1999 5
2000 6
2001 5
2002 7
2003 10
2004 13
2005 9
2006 17
2007 14
2008 11
2009 11
2010 19
2011 15
2012 9
2013 12
2014 11
2015 20
2016 13
2017 12
2018 7
2019 9
2020 13
2021 14
2022 6
2023 10
2024 3

Text availability

Article attribute

Article type

Publication date

Search Results

319 results

Results by year

Filters applied: . Clear all
Page 1
Serial assessment of measurable residual disease in medulloblastoma liquid biopsies.
Liu APY, Smith KS, Kumar R, Paul L, Bihannic L, Lin T, Maass KK, Pajtler KW, Chintagumpala M, Su JM, Bouffet E, Fisher MJ, Gururangan S, Cohn R, Hassall T, Hansford JR, Klimo P Jr, Boop FA, Stewart CF, Harreld JH, Merchant TE, Tatevossian RG, Neale G, Lear M, Klco JM, Orr BA, Ellison DW, Gilbertson RJ, Onar-Thomas A, Gajjar A, Robinson GW, Northcott PA. Liu APY, et al. Among authors: stewart cf. Cancer Cell. 2021 Nov 8;39(11):1519-1530.e4. doi: 10.1016/j.ccell.2021.09.012. Epub 2021 Oct 21. Cancer Cell. 2021. PMID: 34678152 Free PMC article.
Selumetinib in paediatric patients with BRAF-aberrant or neurofibromatosis type 1-associated recurrent, refractory, or progressive low-grade glioma: a multicentre, phase 2 trial.
Fangusaro J, Onar-Thomas A, Young Poussaint T, Wu S, Ligon AH, Lindeman N, Banerjee A, Packer RJ, Kilburn LB, Goldman S, Pollack IF, Qaddoumi I, Jakacki RI, Fisher PG, Dhall G, Baxter P, Kreissman SG, Stewart CF, Jones DTW, Pfister SM, Vezina G, Stern JS, Panigrahy A, Patay Z, Tamrazi B, Jones JY, Haque SS, Enterline DS, Cha S, Fisher MJ, Doyle LA, Smith M, Dunkel IJ, Fouladi M. Fangusaro J, et al. Among authors: stewart cf. Lancet Oncol. 2019 Jul;20(7):1011-1022. doi: 10.1016/S1470-2045(19)30277-3. Epub 2019 May 28. Lancet Oncol. 2019. PMID: 31151904 Free PMC article. Clinical Trial.
Outcomes by Clinical and Molecular Features in Children With Medulloblastoma Treated With Risk-Adapted Therapy: Results of an International Phase III Trial (SJMB03).
Gajjar A, Robinson GW, Smith KS, Lin T, Merchant TE, Chintagumpala M, Mahajan A, Su J, Bouffet E, Bartels U, Schechter T, Hassall T, Robertson T, Nicholls W, Gururangan S, Schroeder K, Sullivan M, Wheeler G, Hansford JR, Kellie SJ, McCowage G, Cohn R, Fisher MJ, Krasin MJ, Stewart CF, Broniscer A, Buchhalter I, Tatevossian RG, Orr BA, Neale G, Klimo P Jr, Boop F, Srinivasan A, Pfister SM, Gilbertson RJ, Onar-Thomas A, Ellison DW, Northcott PA. Gajjar A, et al. Among authors: stewart cf. J Clin Oncol. 2021 Mar 1;39(7):822-835. doi: 10.1200/JCO.20.01372. Epub 2021 Jan 6. J Clin Oncol. 2021. PMID: 33405951 Free PMC article. Clinical Trial.
A phase II trial of selumetinib in children with recurrent optic pathway and hypothalamic low-grade glioma without NF1: a Pediatric Brain Tumor Consortium study.
Fangusaro J, Onar-Thomas A, Poussaint TY, Wu S, Ligon AH, Lindeman N, Campagne O, Banerjee A, Gururangan S, Kilburn LB, Goldman S, Qaddoumi I, Baxter P, Vezina G, Bregman C, Patay Z, Jones JY, Stewart CF, Fisher MJ, Doyle LA, Smith M, Dunkel IJ, Fouladi M. Fangusaro J, et al. Among authors: stewart cf. Neuro Oncol. 2021 Oct 1;23(10):1777-1788. doi: 10.1093/neuonc/noab047. Neuro Oncol. 2021. PMID: 33631016 Free PMC article. Clinical Trial.
Clinical Pharmacokinetics and Pharmacodynamics of Selumetinib.
Campagne O, Yeo KK, Fangusaro J, Stewart CF. Campagne O, et al. Among authors: stewart cf. Clin Pharmacokinet. 2021 Mar;60(3):283-303. doi: 10.1007/s40262-020-00967-y. Epub 2020 Dec 23. Clin Pharmacokinet. 2021. PMID: 33354735 Free PMC article. Review.
Etoposide: an update.
Fleming RA, Miller AA, Stewart CF. Fleming RA, et al. Among authors: stewart cf. Clin Pharm. 1989 Apr;8(4):274-93. Clin Pharm. 1989. PMID: 2653712 Review.
Non-chemotherapy adjuvant agents in TP53 mutant Ewing sarcoma.
Kim JA, Crawford KA, Spada PA, Martin LR, Zhang J, Wong R, Reid JM, Stewart CF, Frank TM, Liu Q, Michalek JE, Keller C. Kim JA, et al. Among authors: stewart cf. Sci Rep. 2023 Sep 1;13(1):14360. doi: 10.1038/s41598-023-40751-z. Sci Rep. 2023. PMID: 37658148 Free PMC article.
Fusion Oncoproteins in Childhood Cancers: Potential Role in Targeted Therapy.
Angione SDA, Akalu AY, Gartrell J, Fletcher EP, Burckart GJ, Reaman GH, Leong R, Stewart CF. Angione SDA, et al. Among authors: stewart cf. J Pediatr Pharmacol Ther. 2021;26(6):541-555. doi: 10.5863/1551-6776-26.6.541. Epub 2021 Aug 16. J Pediatr Pharmacol Ther. 2021. PMID: 34421403 Free PMC article. Review.
Topoisomerase I interactive agents.
Kirstein MN, Turner PK, Stewart CF. Kirstein MN, et al. Among authors: stewart cf. Cancer Chemother Biol Response Modif. 2002;20:99-123. Cancer Chemother Biol Response Modif. 2002. PMID: 12703202 Review.
Reducing irinotecan-associated diarrhea in children.
Wagner LM, Crews KR, Stewart CF, Rodriguez-Galindo C, McNall-Knapp RY, Albritton K, Pappo AS, Furman WL. Wagner LM, et al. Among authors: stewart cf. Pediatr Blood Cancer. 2008 Feb;50(2):201-7. doi: 10.1002/pbc.21280. Pediatr Blood Cancer. 2008. PMID: 17570704 Review.
319 results